A novel angiotensin II peptide vaccine without an adjuvant in mice.

ABSTRACT:

Objectives

We recently developed a novel peptide, AJP001, that possesses both a mouse T-cell epitope and adjuvant action. Direct conjugation to the antigen is useful for peptide vaccines without the addition of adjuvants. In this study, the efficacy of an angiotensin (Ang) II and AJP001-conjugated peptide vaccine (AJ-Ang II) was evaluated in mice.

Methods

The anti-Ang II antibody titer was measured in Balb/C mice following three injections of AJ-Ang II at 2-week intervals. SBP was measured during vaccination of Balb/C mice treated with Ang II infusion (1 μg/kg per min).

Results

AJ-Ang II treatment resulted in an increase in the anti-Ang II antibody titer in a dose-dependent manner without the addition of adjuvants. In the analysis of the humoral immune response, AJ-An

SUBMITTER: Nakamaru R 

PROVIDER: S-EPMC7752219 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature